文献速递自身炎症与 IgG4 相关病

Blau综合征对托珠单抗反应良好:一例病例报告及聚焦文献综述

Blau syndrome with good Reponses to Tocilizumab: A case report and focused literature review.
PubMed 文献 · Semin Arthritis Rheum · 2017-09-25

本文报告首例中国Blau综合征(BS)患者,对现有治疗抵抗,使用托珠单抗后病情快速静止,泼尼松减至每日8mg。系统文献综述纳入29篇文献共45例BS患者,其中24例接受生物制剂治疗,22例好转。作者认为对有发热、淋巴结肿大和肝脾肿大的BS患者,托珠单抗可能是更好的选择。

要点

  • 13岁中国男孩Blau综合征患者,英夫利西单抗治疗时葡萄膜炎加重,托珠单抗治疗后良好控制,泼尼松减至每日8mg。
  • 系统文献综述纳入29篇文献共45例BS患者,24例接受生物制剂治疗,22例恢复。
  • 文献中用于难治性BS的生物制剂包括依那西普、英夫利西单抗、阿达木单抗、卡那奴单抗和阿那白滞素。

核心结论

  • 关于生物制剂使用的病例报告结果不一,症状多样性可能源于NOD2突变的功能差异。
  • 作者认为对有发热、淋巴结肿大和肝脾肿大的BS患者,托珠单抗可能是更好的选择。

研究设计与样本

  • 病例报告加系统文献综述,报告首例中国Blau综合征患者使用托珠单抗的经验。
  • 文献综述纳入29篇文献,共提供45例Blau综合征病例。

主要发现

  • 13岁中国男孩Blau综合征患者,英夫利西单抗治疗时葡萄膜炎加重,使用托珠单抗后良好控制,泼尼松减至每日8mg。
  • 45例Blau综合征患者中,24例接受生物制剂治疗,22例恢复。
  • 文献中用于难治性Blau综合征的生物制剂包括依那西普、英夫利西单抗、阿达木单抗、卡那奴单抗和阿那白滞素。

关键数值与推荐

  • Blau综合征维持治疗中,使用免疫抑制剂时糖皮质激素维持剂量通常可能无法减至每日15mg以下。
  • 病例报告中患者使用托珠单抗后泼尼松减至每日8mg。
  • 文献综述纳入29篇文献共45例Blau综合征病例,其中24例接受生物制剂治疗,22例恢复。

临床怎么用

  • 作者认为对有发热、淋巴结肿大和肝脾肿大的Blau综合征患者,托珠单抗可能是更好的选择。

局限性

  • 关于生物制剂使用的病例报告结果不一。
  • 症状多样性可能源于NOD2突变的功能差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Blau syndrome (BS), a rare auto-inflammatory granulomatous disease, is a progressive disorder. Usually the maintenance dose of glucocorticoid may not be tapered below 15 mg per day while immunosuppressives is used. There has been some experience with biologic agents in refractory BS patients. The objective of this study is to describe the case of a BS patient benefiting from Tocilizumab, a humanized monoclonal antibody against interleukin 6 receptor. METHODS: We report the first Chinese patient with BS who was resistant to currently available therapies but had rapid quiescence after using Tocilizumab. We also conducted a systematic literature review about the current treatments of BS. RESULTS: A 13-year-old Chinese boy with BS, whose uveitis got worsened when treated with Infliximab, was well-controlled after taking Tocilizumab and prednisone was tapered off to a dose of 8mg per day. We identified 29 manuscripts providing 45 BS cases. Among these patients, 24 underwent biological treatments and 22 of them recovered. In these 29 manuscripts, the biological agents used to treat refractory BS included Etanercept, Infliximab, Adalimumab, Canakinumab and Anakinra. CONCLUSIONS: Case reports on the use of biological agents have yielded mixed results. The diversity of the symptoms may be due to functional differences in NOD2 mutations. For BS patients with fever, lymphadenopathy and hepatosplenomegaly, Tocilizumab may be a better choice.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Lu L, Shen M, Jiang D, et al. Blau syndrome with good Reponses to Tocilizumab: A case report and focused literature review. Semin Arthritis Rheum. 2017. PMID: 29110911. doi:10.1016/j.semarthrit.2017.09.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。